CIK 0001855644 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in E9 · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Net income (USD) | -68.7 M | -60.4 M | -25.7 M |
| Diluted EPS (USD/shares) | -1.06 | -2.09 | -141.97 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-30 | S-8 | FORM S-8 | |
| 2026-08-18 | 144 | 144 | |
| 2026-08-17 | 144 | 144 | |
| 2026-08-17 | 8-K | FORM 8-K items 7.01,9.01 | 2026-08-17 |
| 2026-08-14 | 144 | 144 | |
| 2026-08-13 | 144 | 144 | |
| 2026-08-11 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-08-11 |
| 2026-08-11 | 10-Q | 10-Q | 2026-06-30 |
| 2026-07-01 | 8-K | FORM 8-K items 7.01,9.01 | 2026-07-01 |
| 2026-06-22 | 3 | 3 | 2026-04-17 |
| 2026-06-22 | 4 | 4 | 2026-06-17 |
| 2026-06-22 | 4 | 4 | 2026-06-17 |
| 2026-06-22 | 4 | 4 | 2026-06-17 |
| 2026-06-22 | 4 | 4 | 2026-06-17 |
| 2026-06-22 | 4 | 4 | 2026-06-17 |
| 2026-06-22 | 4 | 4 | 2026-06-17 |
| 2026-06-22 | 4 | 4 | 2026-06-17 |
| 2026-06-18 | 8-K | FORM 8-K items 5.02,5.07,9.01 | 2026-06-17 |
| 2026-05-22 | DEFA14A | DEFA14A | |
| 2026-05-22 | 8-K | FORM 8-K items 5.02 | 2026-05-20 |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-12 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-07 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-05-07 |
| 2026-05-07 | 10-Q | 10-Q | 2026-03-31 |
Forms on file (last 1,000): 8-K 100, 4 82, 3 39, CORRESP 23, 10-Q 17, UPLOAD 17, SCHEDULE 13G/A 15, SC 13G 15. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ZURA (0.002 USD), /gw/filings/filings?ticker=ZURA&form=8-K, /gw/filings/facts?ticker=ZURA&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange